Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis
Journal of Rheumatic Diseases
; : 293-302, 2017.
Article
ي En
| WPRIM
| ID: wpr-217321
المكتبة المسؤولة:
WPRO
ABSTRACT
OBJECTIVE:
To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs).METHODS:
A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics.RESULTS:
From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration.CONCLUSION:
Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA.Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Osteoarthritis
/
Anti-Inflammatory Agents, Non-Steroidal
/
Ibuprofen
/
Naproxen
/
Incidence
/
Celecoxib
/
Anti-Inflammatory Agents
نوع الدراسة:
Clinical_trials
/
Incidence_studies
/
Prognostic_studies
/
Systematic_reviews
اللغة:
En
مجلة:
Journal of Rheumatic Diseases
السنة:
2017
نوع:
Article